Programm & Abstracts                 "Innovationen in der Augenheilkunde"

Aktuelle Tagungsinformationen
   News and Updates

Anmeldung zur Tagung
   Registration
Hotelbuchung
   Hotel Registration
Grußwort
   Welcome address
Beteiligte Gesellschaften
   Societies involved
Eröffnung des Kongresses
   Opening Ceremony
Preise
   Awards
Wissenschaftliches Programm
   Scientific program
Posterpräsentationen
   Poster Presentation
Kurse
   Courses
Begleitende Veranstaltungen
   Collateral Events
Rahmenprogramm
   Social program
Jubiläumsparty
   Jubilee Party
DOG Information
   DOG Information
Allgemeine Informationen
   General Information
Autorenindex
   Index of Authors
Ausstellerliste
   Exhibitors
Sponsoren
   Sponsors
Teilnahmegebühren
   Registration fees
Impressum



DOG Homepage

Posterior Capsule Opacification of the PMMA-IOL 751A® 2-5 Years Post-operatively

1Kojetinsky C., 2Porstmann A. U., 3Anders N., 2Nimsgern C., 2Müller V., 2Hartmann C., 2Tetz M.,
1Ludwig-Maximilians-Universität München, Augenklinik (München)
2Humboldt-Universität zu Berlin, Charité Campus Virchow-Klinikum, Augenklinik (Berlin)
3Augenklinik am Gendarmenmarkt (Berlin)

Purpose: Development of Posterior capsule opacification (PCO) is strongly influenced by material and design of the implanted intraocular lens (IOL). Some studies suggested a remarkebly strong PCO by PMMA-IOLs. A clinical study was performed to estimate the rate of PCO of the PMMA-IOL 751A® (Pharmacia).
Method: 36 eyes of 26 patients (mean age at examination time: 73,5 [60-87]) years were examined 2-5 years after implantation of the PMMA-IOL 751A®. All patients had standardized cataract surgery (Phacoemulsification) by the same surgeon. Postoperative therapy followed the standard protocoll. Patients with any ocular pathology resp. systemic disease influencing PCO development or systemic medication were excluded. Visual acuity and the rate of YAG-capsulotomies was determined; PCO was quantified by the EPCO®-picture analysis programme.
Results: 3 years postoperatively the rate of YAG-capsulotomies was 0%, after 4 years 23,1%. The EPCO®-score was in median 1,093 (0,347-3,0) and the median of visual acuity 0,80 (0,4-1,0) after 4 years.
Conclusions: The rate of YAG-capsulotomies ot the PMMA-IOL 751A® obtained in our study of 0% after 3 years is much lower than the rates reported from other investigations for PMMA-IOLs (ca. 22-38%) aswell as for acrylic IOLs (ca. 6-7%). In conclusion, we can not confirm previous studies which showed an increase of PCO by PMMA-IOLs. To compare and evaluate the EPCO-scores further investigations are needed.

Zurück/Back